复宏汉霖海外布局调整：KGBio“下车”，Abbott“扩容”

财中社02-24

2月24日，复宏汉霖（02696）发布公告，公司终止与PT Kalbe Genexine Biologics（下称KGBio）就汉斯状®（斯鲁利单抗注射液）在东南亚、中东及北非地区国家的独家开发及商业化许可权力。　　同日，公司与Abbott Products Operations AG（下称Abbott）签订修订的许可协议，扩大原Abbott的许可区域。新增许可区域覆盖亚洲、中东、非洲及东欧等42...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2613791226?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-24 17:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613791226","market":"us","top_or_hot":-1,"title":"复宏汉霖海外布局调整：KGBio“下车”，Abbott“扩容”","media":"财中社","content":"<div>\n<p>2月24日，复宏汉霖（02696）发布公告，公司终止与PT Kalbe Genexine Biologics（下称KGBio）就汉斯状®（斯鲁利单抗注射液）在东南亚、中东及北非地区国家的独家开发及商业化许可权力。　　同日，公司与Abbott Products Operations AG（下称Abbott）签订修订的许可协议，扩大原Abbott的许可区域。新增许可区域覆盖亚洲、中东、非洲及东欧等42...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202602243652813832.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复宏汉霖海外布局调整：KGBio“下车”，Abbott“扩容”</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复宏汉霖海外布局调整：KGBio“下车”，Abbott“扩容”\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-24 17:41 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202602243652813832.html><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2月24日，复宏汉霖（02696）发布公告，公司终止与PT Kalbe Genexine Biologics（下称KGBio）就汉斯状®（斯鲁利单抗注射液）在东南亚、中东及北非地区国家的独家开发及商业化许可权力。　　同日，公司与Abbott Products Operations AG（下称Abbott）签订修订的许可协议，扩大原Abbott的许可区域。新增许可区域覆盖亚洲、中东、非洲及东欧等42...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202602243652813832.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"http://finance.eastmoney.com/a/202602243652813832.html","article_id":"2613791226","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613791226","pubTimestamp":1771926105,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"2月24日，复宏汉霖（02696）发布公告，公司终止与PTKalbeGenexineBiologics（下称KGBio）就汉斯状?（斯鲁利单抗注射液）在东南亚、中东及北非地区国家的独家开发及商业化许可权力。同日，公司与AbbottProductsOperationsAG（下称Abbott）签订修订的许可协议，扩大原Abbott的许可区域。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4082":"医疗保健设备","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","BK4592":"伊斯兰概念","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","BK4504":"桥水持仓","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4568":"美国抗疫概念","SGXZ41872573.SGD":"ALLIANZ SGD INCOME PLUS \"AM\" (SGD) INC","BK4588":"碎股","SG9999002224.SGD":"Allianz Global High Payout SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1989763690.USD":"东方汇理世代食品基金A2 Acc","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1989763427.SGD":"CPR Invest - Food For Generations A2 Acc SGD-H","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","02696":"复宏汉霖","LU0882574055.USD":"富达全球健康医疗A ACC","BK1161":"生物科技","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU1721429402.USD":"BNP PARIBAS SMART FOOD \"C\" (USD) ACC","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","LU1721429741.USD":"BNP PARIBAS SMART FOOD \"CRH\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","LU0058720904.USD":"联博国际健康护理基金A","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4581":"高盛持仓","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","ABT":"雅培","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC"},"translate_title":"Henlius's overseas layout adjustment: KGBio \"gets off\", Abbott \"expands\"","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1.5,"ABT":1.5},"content_text":"2月24日，复宏汉霖（02696）发布公告，公司终止与PT Kalbe Genexine Biologics（下称KGBio）就汉斯状®（斯鲁利单抗注射液）在东南亚、中东及北非地区国家的独家开发及商业化许可权力。　　同日，公司与Abbott Products Operations AG（下称Abbott）签订修订的许可协议，扩大原Abbott的许可区域。新增许可区域覆盖亚洲、中东、非洲及东欧等42个国家/地区。许可产品的监管里程碑款项不超4600万美元，商业销售里程碑合计不超8000万美元。　　根据协议修订，公司将终止在KGBio终止区域内的独家许可权。KGBio将转让该区域内的上市许可，公司据此支付不超过3375万美元里程碑款项，监管里程碑同步下调。修订后，原协议中的销售里程碑和特许权使用费约定仅适用于印度尼西亚。（文章来源：财中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613791226","isCrawlerRequest":true}